

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Long distance airborne transmission of SARS-CoV-2, people in intensive care with COVID-19 in Australia, vaccination and long COVID

#### Peer reviewed journals featured:

- Systematic reviews on:
  - Long distance airborne transmission of SAR-CoV-2 [here](#) and associated editorial [here](#)
  - Long COVID in children and adolescents [here](#)
  - Baricitinib in hospitalised COVID-19 patients [here](#)
- A randomised controlled trial of interrupted vs continued methotrexate treatment for COVID-19 booster immunity in adults with inflammatory conditions [here](#) and associated commentary [here](#)
- Narrative reviews on:
  - Breakthrough SARS-CoV-2 infections after COVID-19 immunisation [here](#)
  - Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants [here](#)
- Observational studies on:
  - Comirnaty (Pfizer) vaccine against Omicron in children aged 5 to 11 years [here](#)
  - People in intensive care with COVID-19 in Australia [here](#)
  - Emergence of Omicron lineages BA.4 and BA.5 in South Africa [here](#)
  - Long COVID burden and risk factors in the UK [here](#)
  - Myocarditis and pericarditis after mRNA vaccination [here](#), [here](#) and associated commentary [here](#)
  - Risk factors for multisystem inflammatory syndrome in children [here](#)
  - COVID-19 disease severity in US veterans during Omicron and Delta periods [here](#)
  - Maternal immune response and antibody transfer post COVID-19 vaccination [here](#)
  - International electronic health record-derived patient profiles for long COVID [here](#)
- An editorial on COVID-19 vaccine efficacy in a rapidly changing landscape [here](#)
- Commentary on:
  - How long does SARS-CoV-2 stay in the body? [here](#)
  - Restoring clinical services by aligning clinical and management leadership [here](#)

#### Letters and correspondence discussed:

- Duration of culturable virus shedding in Omicron (BA.1) infection [here](#)
- Immunogenicity and safety of beta-adjuvanted recombinant booster vaccine [here](#)
- Early SARS-CoV-2 reinfections within 60 days and implications for retesting policies [here](#)

## Pre-peer review articles featured:

- The impact of COVID-19 vaccination on long COVID [here](#)
- Vaccination effectiveness against Omicron infection, symptomatic disease, and hospitalisation [here](#)
- COVID-19 rebound after paxlovid and molnupiravir during January-June 2022 [here](#)
- The impact of the Omicron emergence on clinical epidemiology of COVID-19 in inpatients [here](#)
- Efficacy of monoclonal antibodies and direct antiviral agents against Omicron sublineages [here](#)
- Evidence of recent Epstein-Barr virus reactivation in individuals experiencing long COVID [here](#)
- The natural course of post COVID-19 condition and its implications for trial design [here](#)
- Pre-Omicron breakthrough infection and cross-neutralisation against Omicron BA.1 [here](#)
- Comirnaty (Pfizer) effectiveness against Delta & Omicron variants in teens [here](#)
- Omicron BA.4/5 wave compared with previous waves in South Africa [here](#)
- Points-based models for predicting severe disease related to COVID-19 with Omicron variant [here](#)

## Guidance and reports

- The World Health Organization published updates of its clinical management guideline [here](#), and weekly epidemiological report [here](#)
- The UK Health Security Agency published an update on SARS-CoV-2 variants of concern and variants under investigation [here](#)

## News and blogs

- What Omicron's BA.4 and BA.5 variants mean for the pandemic [here](#)
- COVID-19 failures show the US needs a national public health system [here](#)
- Breathalysers - diagnostics to take your breath away [here](#)
- Fast-evolving COVID-19 variants complicate vaccine updates [here](#)
- COVID-19 was twice as deadly in poorer countries [here](#)
- COVID-19 antibody drugs have saved lives - so why aren't they more popular? [here](#)
- A podcast on the US decision to authorise vaccines for youngest of kids [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

### Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(long COVID\)](#), [surgery and COVID-19](#), and [rapid testing](#).